Search results
1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever | The Motley Fool
The Motley Fool· 8 hours agoWhen looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy....
Where Will Novo Nordisk Be in 10 Years?
Motley Fool via Yahoo Finance· 8 hours agoThese are just a few examples but there are even more healthcare companies vying for share of the lucrative GLP-1 drug market. Novo Nordisk's growth rate...
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 2 hours agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
Hims & Hers Selling GLP-1 Weight Loss Drugs Like Wegovy for 85% Less: What to Know
Healthline via AOL· 3 days agoTelehealth company Hims & Hers announced they will begin selling off-brand GLP-1 drugs similar to...
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
InvestorPlace· 2 days agoFor investors looking at companies providing GLP-1 drugs, there are certainly plenty of factors to...
Bye bye Taylor Swift's jet, weight loss drug research, and summer travel spots: Lifestyle news...
Quartz· 8 hours agoNew research this month is the latest to link the use of Ozempic, Wegovy, and other GLP-1 drugs to a...
3 High-Flying Stocks That Could Soar Even More
Motley Fool via Yahoo Finance· 10 hours agoSo far this year, the big pharma stock is up nearly 40%. I think Lilly is just getting started. Why am I so optimistic about Lilly? For one thing, it's...
The rise and fall of Elizabeth Holmes, the former Theranos CEO
INSIDER via Yahoo News· 5 hours agoWith his blessing, she founded Real-Time Cures, later changing the company's name to Theranos....
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Motley Fool via Yahoo Finance· 11 hours agoAs of March 31, 2024, AbbVie's cash position stood above $18 billion. I especially like AbbVie's...
Down 72%. Is Ginkgo Bioworks a Buy on the Dip?
The Motley Fool via AOL· 12 hours agoIt has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell ...
